Sofinnova BioEquities Enhanced Master Fund, LP
Sofinnova BioEquities Enhanced Master Fund, LP is a hedge fund based in Menlo Park, California. According to its most recent Form D, filed Oct 9, 2026, the fund has sold $87,225,567 of interests to 26 investors since its first sale in Oct 2022. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Sofinnova BioEquities GP LLC; Sofinnova Investments, Inc.
Performance
No verified returns have been reported for this fund. As a rough guide, Sofinnova Investments, Inc., which manages it, disclosed U.S. stock holdings that returned an estimated +20.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based only on its public 13F filings. Over a longer period, Q3 2024 to Q2 2026, the estimate is +84.2% (S&P 500: +37.2%).
This estimate covers the firm's whole disclosed long U.S. stock portfolio. It is not this fund's return and excludes dividends, fees, shorts, derivatives, bonds, cash and trading within each quarter.
Is this your fund? Report your monthly returns · How performance works
- Total raised
- $87,225,567Cumulative sales reported on Form D
- Investors
- 26
- First sale
- Oct 3, 2022
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Sofinnova BioEquities GP LLC; Sofinnova Investments, Inc
- Latest Form D
- Oct 9, 2026
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about Sofinnova BioEquities Enhanced Master Fund, LP
What is the minimum investment for Sofinnova BioEquities Enhanced Master Fund, LP?
Sofinnova BioEquities Enhanced Master Fund, LP's latest Form D, filed Oct 9, 2026, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in Sofinnova BioEquities Enhanced Master Fund, LP?
Sofinnova BioEquities Enhanced Master Fund, LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has Sofinnova BioEquities Enhanced Master Fund, LP raised?
Sofinnova BioEquities Enhanced Master Fund, LP reports $87,225,567 sold from 26 investors on its Form D filed Oct 9, 2026. This is cumulative sales since the offering began, not current assets or performance.
Where is Sofinnova BioEquities Enhanced Master Fund, LP based?
Sofinnova BioEquities Enhanced Master Fund, LP is based in Menlo Park, California and is managed by Sofinnova Investments, Inc..
When did Sofinnova BioEquities Enhanced Master Fund, LP launch?
Sofinnova BioEquities Enhanced Master Fund, LP reports its first sale in Oct 2022.
Size compared with every hedge fund
Raised more than 65% of the 1,060 hedge funds based in California, and more than 55% of all 10,308 that report sales.